Melanotan II

The ‘tanning peptide’ with the thinnest evidence and the clearest documented harms on this site.

Evidence tier: C (no modern controlled human efficacy trials for the cosmetic use; early small mechanistic studies only) · Regulatory status in Canada: not approved; sold gray-market as an unapproved substance · Community risk profile: high — unlike most Tier-C compounds, Melanotan II has documented serious adverse events, not just an absence of data.

C-harm

What it is

Melanotan II ("MT-II," the "Barbie drug," "the tanning peptide") is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH). It stimulates melanocortin receptors, which drives melanin production (tanning) and, via a separate receptor, sexual arousal. It's used off-label and injected for a cosmetic tan — often with minimal or no UV exposure — and sometimes for libido. It is not the same as afamelanotide (Scenesse), a related but regulated melanocortin agonist approved for a rare photodermatosis.

What People Use it For

  • Cosmetic tanning — the dominant use; injected to darken skin, popularized on TikTok as the "Barbie drug."

  • Libido / erectile effect — the melanocortin arousal pathway; the original research interest.

  • Appetite effects — sometimes cited anecdotally; not an established use. Sourced almost entirely gray-market as lyophilized powder for self-injection.

What The Evidence Shows

This is a Tier Ccompound and the gap is stark:

  • Mechanism is real but old and small. Early human work established that melanocortin agonists affect erection and sexual motivation (Wessells et al., Int J Impot Res 2000) — small, mechanistic, and not about cosmetic tanning.

  • No modern controlled efficacy or safety trials support the cosmetic-tanning use at the doses people self-inject. The community claim rests on mechanism plus anecdote, not outcome trials.

  • Critically — and unlike most Tier-C compounds — the harm side is NOT empty. There is published case-report evidence of serious events. So the honest summary is not "we don't know anything," it's "we know little about benefit and have specific reasons for concern about harm."

Why the evidence is thin: no sponsor, no approval pathway for a cosmetic tan, and an unapproved substance can't run the trials that would characterize it. Thin efficacy data here does not mean "harmless" — the safety signals below exist despite the small literature.

Regulatory Status - Canada

Melanotan II is not approved by Health Canada for any use and is sold as an unapproved/gray-market substance. It is not a licensed cosmetic or drug; "research chemical" / "not for human use" labeling is a seller's legal shield, not a safety statement. (Afamelanotide/Scenesse — a different, regulated melanocortin agonist — should not be conflated with gray-market MT-II.)

Risks & Red Flags

Melanotan II has documented, specific harms, which is what separates it from compounds that are merely under-studied:

  • Cardiovascular / thrombotic: a published case report links MT-II to renal infarction (Francis & Butler, CEN Case Rep 2020) — a serious vascular event in a young cosmetic user.

  • Melanoma / mole changes: melanocyte stimulation drives darkening and change in existing moles; case reports describe changing/atypical melanocytic lesions and concern for melanoma. Any new or changing mole in a user warrants dermatologic assessment.

  • Common/expected: nausea, facial flushing, spontaneous erections, appetite suppression, darkening of moles and freckles.

  • Sourcing-linked: non-sterile self-injection, unverified purity, and unknown actual dose (see §6). The combination — a serious vascular case report plus a plausible melanoma concern plus gray-market supply — is why the community risk profile is high despite the small literature.

Sourcing red flags Melanotan II is bought as gray-market powder and self-reconstituted:

  • Unapproved, unverified product: no regulated source exists; identity, purity, and dose are unconfirmed.

  • "Purity" ≠ potency: a "99% pure" claim says nothing about the actual amount you're injecting.

  • DIY reconstitution and injection: the mg↔mcg↔units↔mL error chain applies here as with any injected peptide (see the reconstitution-math page), plus non-sterile technique risk.

2026 dermatology literature keeps adding harm reports.The melanoma concern with Melanotan II is no longer hypothetical in the case literature: a 2026 JAAD Case Reports paper documents five primary melanomas in situ in a single patient with melanotan and tanning-bed use. Separately, a 2026 International Journal of Dermatologycommentary — "Unregulated Melanotan Use Promoted via Social Media: Emerging Dermatologic and Public Health Risks" — names the exact pipeline this site is concerned with: an unregulated injectable, marketed peer-to-peer online, with dermatologic and public-health consequences. These are case-level and commentary-level evidence, which is precisely why Melanotan II sits at Tier C with harm flags rather than anywhere higher.

The Honest Bottom Line

Melanotan II is the clearest case on Substrate of a compound where the community use runs far ahead of any evidence and the documented harms are real. There are no adequate human efficacy or safety trials — but there are published case reports of serious events, and a legitimate concern about changes to moles and melanoma risk in a compound that drives melanogenesis.

This is a Tier C page that carries a harm flag for a reason: the risks aren't hypothetical extrapolation, they're in the case literature. If any compound on this site argues for talking to a clinician before use — especially a dermatologist about your moles — it's this one.

How To Lower Your Risk

  • Understand this isn't just "unproven" — it has specific documented harms. The vascular case report and the melanoma concern are the reasons to take this one seriously, not generic caution.

  • Skin surveillance is non-negotiable if used: any new, changing, or atypical mole → dermatology, and mention MT-II use explicitly.

  • This does not replace sun protection and is not an approved way to "tan safely."

  • Vascular symptoms are an emergency: flank/abdominal pain, chest pain, or neurologic symptoms in a user warrant urgent assessment given the thrombotic case evidence.

  • Tell a clinician (see the clinician-conversation page), especially with any cardiovascular risk or personal/family melanoma history.

  • If the goal is cosmetic, weigh that a documented serious-harm profile is being taken on for an appearance change.

Sources

  1. Wessells H, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II. Int J Impot Res. 2000. PMID: 11035391.

  2. Francis L, Butler MG. Melanotan II: a possible cause of renal infarction — review of the literature and case report. CEN Case Rep. 2020. PMID: 31953620. doi:10.1007/s13730-020-00447-z

  3. JAAD Case Rep 2026 — Five primary melanomas in situ, melanotan user — 10.1016/j.jdcr.2026.05.009

  4. Int J Dermatol 2026 — Unregulated melanotan use promoted via social media — 10.1111/ijd.70286

‹ Orforglipron

BPC-157 ›


Substrate is an independent educational harm-reduction resource. It is not medical, legal, or regulatory advice, and it is not a substitute for a licensed clinician. Compounds discussed are largely unapproved in Canada; nothing here endorses their use. Confirm anything health-related with a qualified professional. Built by a medical-sciences student — not a seller and not a clinic.